Compare State Street SPDR S&P Biotech ETF (XBI) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR S&P Biotech ETF vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? State Street SPDR S&P Biotech ETF trades at $159.8, while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.39. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| XBI | XDTE | |
|---|---|---|
Sector | Broad Market / Factor | Income / Options Overlay |
52-Week High | $169.55 | $44.76 |
52-Week Low | $93.43 | $36.00 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
XDTE trades at $38.60, down 0.5% on the day, with technical indicators showing bearish momentum as moving averages signal selling pressure. The ETF's weekly dividend strategy has generated significant attention, with recent payouts ranging from $0.09 to $0.26 per share. However, financial ratios remain unavailable, limiting fundamental analysis. Recent news coverage highlights concerns about the sustainability of XDTE's high yield strategy and fee structure compared to alternatives.
The outlook for XDTE appears cautious due to questions about dividend sustainability and competitive fee pressures. While the weekly income strategy attracts yield-seeking investors, structural risks and bearish technical signals suggest limited near-term upside potential. Investors should weigh the high distribution yield against potential total return underperformance in rising markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
